outbreak
sever
acut
respiratori
syndrom
infect
began
wuhan
china
emerg
primari
concern
world
world
health
organ
announc
risk
assess
coronaviru
diseas
high
global
level
fatal
case
rapidli
increas
march
peopl
infect
peopl
die
south
korea
without
specif
treatment
viru
treatment
option
studi
addit
support
care
evid
show
use
convalesc
plasma
treat
emerg
viral
infect
includ
sar
middl
east
respiratori
syndrom
mer
ebola
viru
diseas
avian
flu
improv
surviv
rate
patient
whose
condit
worsen
even
convent
howev
safeti
efficaci
convalesc
plasma
treatment
known
report
two
case
sever
patient
present
acut
respiratori
distress
syndrom
ard
show
favor
clinic
cours
convalesc
plasma
infus
first
report
use
convalesc
plasma
treat
case
infect
korea
previous
healthi
man
visit
commun
health
center
februari
present
day
fever
cough
underw
examin
via
realtim
revers
transcript
polymeras
chain
reaction
rrtpcr
diagnos
admit
local
public
medic
center
mg
hydroxychloroquin
daili
start
chest
radiograph
obtain
day
show
mild
opac
right
lower
lung
lopinavirritonavir
mg
twice
daili
ad
howev
day
oxygen
demand
increas
transfer
tertiarycar
hospit
time
arriv
patient
subject
dyspnea
lmin
oxygen
flow
via
nasal
cannula
respiratori
rate
time
per
minut
chest
radiograph
demonstr
rapidli
aggrav
bilater
infiltr
routin
blood
test
found
white
blood
cell
wbc
count
lymphopenia
creactiv
protein
crp
lactic
dehydrogenas
ldh
elev
mgl
iul
routin
chemistri
electrolyt
blood
coagul
test
reveal
abnorm
except
mildli
elev
aspart
transaminas
level
interleukin
increas
pgml
serial
bacteri
cultur
polymeras
chain
reaction
pcr
respiratori
virus
neg
intub
mechan
ventil
care
start
accord
manag
ard
despit
continu
use
lopinavirritonavir
hydroxychloroquin
empir
antibiot
remain
febril
aggrav
oxygen
profil
chest
imag
laboratori
test
show
elev
crp
mgl
pgml
day
arteri
blood
ga
analysi
show
consist
sever
ard
intraven
methylprednisolon
mgkgday
daili
start
day
convalesc
plasma
obtain
male
donor
recov
day
diagnos
present
fever
cough
pneumonia
howev
show
complet
recoveri
symptom
time
plasma
donat
met
blood
donor
elig
criteria
plasma
donat
includ
age
weight
reasonables
antecubit
vein
also
allogen
donor
screen
test
defin
enforc
rule
blood
manag
act
korea
accept
transfus
donor
apheresi
perform
spectra
optia
apheresi
system
cmnc
softwar
spectra
optia
idl
tube
set
terumo
bct
lakewood
co
usa
ml
convalesc
plasma
collect
igg
antibodi
plasma
measur
enzymelink
immunosorb
assay
elisa
novel
coronaviru
igg
elisa
kit
epitop
diagnost
san
diego
ca
usa
optic
densiti
od
ratio
igg
cutoff
valu
plasma
divid
two
dose
administ
patient
hour
interv
dose
given
hour
advers
reaction
occur
administr
convalesc
plasma
fever
subsid
oxygen
demand
decreas
sinc
day
patient
condit
much
improv
decreas
crp
normal
rang
mgl
pgml
respect
day
increas
fig
chest
xray
reveal
resolut
lung
infiltr
fig
quantifi
detect
rnadepend
rna
polymeras
region
gene
rrtpcr
valu
cycl
threshold
ct
chang
day
day
plasma
infus
fig
neg
day
patient
underw
tracheostomi
current
success
wean
mechan
ventil
woman
medic
histori
hypertens
develop
fever
myalgia
diagnos
via
rrtpcr
march
next
day
admit
local
public
medic
center
receiv
hydroxychloroquin
mg
daili
lopinavirritonavir
mg
twice
daili
empir
antibiot
howev
day
transfer
tertiarycar
hospit
due
increas
oxygen
demand
worsen
infiltr
shadow
left
lower
lung
time
oxygen
satur
check
lmin
oxygen
flow
via
nasal
cannula
respiratori
rate
time
per
minut
routin
blood
test
show
mild
leukocytosi
lymphopenia
elev
crp
ldh
mgl
pgml
iul
respect
routin
chemistri
electrolyt
blood
coagul
test
show
abnorm
bacteri
cultur
pcr
respiratori
virus
neg
receiv
high
flow
oxygen
therapi
bilater
infiltr
oxygen
deterior
intub
mechan
ventil
care
start
day
intraven
methylprednisolon
mgkgday
daili
also
ad
sustain
high
fever
rapidli
increas
crp
mgl
wbc
persist
lymphopenia
fell
consist
sever
ard
appli
prone
posit
accord
manag
ard
use
steroid
chest
imag
oxygen
demand
began
improv
day
convalesc
plasma
obtain
male
donor
recov
day
diagnos
present
fever
cough
pneumonia
howev
show
complet
recoveri
serial
pcr
neg
hospit
discharg
donor
screen
plasma
collect
perform
mention
case
od
ratio
igg
plasma
administ
patient
way
case
advers
reaction
plasma
transfus
leukocytosi
lymphopenia
immedi
recov
convalesc
plasma
infus
day
densiti
bilater
infiltr
chest
xray
much
improv
increas
level
crp
also
recov
normal
rang
fig
quantifi
rrtpcr
valu
ct
chang
day
day
plasma
infus
fig
patient
success
extub
discharg
hospit
day
neg
day
studi
approv
institut
review
board
irb
sever
hospit
irb
particip
written
inform
consent
imag
publish
agreement
patient
studi
therapeut
benefit
plasma
transfus
cure
person
infecti
diseas
began
new
antibiot
antivir
agent
vaccin
develop
administr
convalesc
plasma
common
treatment
still
import
treatment
absenc
specif
treatment
new
infecti
decad
convalesc
plasma
prove
effect
potenti
treatment
patient
avian
system
review
metaanalysi
evalu
clinic
effect
convalesc
plasma
show
statist
signific
reduct
context
convalesc
plasma
promis
treatment
option
sever
patient
seen
two
case
receiv
lopinavirritonavir
hydroxychloroquin
show
persist
fever
rapidli
aggrav
hypoxemia
progress
bilater
infiltr
accord
criteria
sever
ard
convalesc
plasma
infus
patient
show
improv
oxygen
chest
xray
decreas
inflammatori
marker
viral
load
intraven
methylprednisolon
start
convalesc
plasma
infus
case
use
corticosteroid
begin
routin
treatment
current
guidelin
recommend
system
corticosteroid
given
routin
treatment
due
lack
evid
clinic
efficaci
mortal
howev
decid
start
corticosteroid
patient
condit
rapidli
deterior
ard
methylprednisolon
administ
one
day
two
day
plasma
infus
case
case
respect
serial
laboratori
oxygen
paramet
show
rapid
improv
right
corticosteroid
administr
even
convalesc
plasma
infus
ard
partli
caus
cytokin
storm
host
immun
autopsi
patient
die
show
diffus
alveolar
damag
exud
inflamm
similar
seen
sar
merscov
theoret
system
corticosteroid
may
role
dampen
excess
lung
damag
due
inflammatori
recent
articl
risk
factor
associ
ard
death
among
patient
show
treatment
methylprednisolon
might
benefici
reduc
risk
death
patient
develop
howev
corticosteroid
also
thought
inhibit
proper
immun
respons
viral
clearanc
delay
antibodi
convalesc
plasma
infus
might
play
role
coexist
benefit
concern
corticosteroid
use
antibodi
contain
convalesc
plasma
suppress
anim
studi
passiv
transfer
antibodi
provid
total
protect
well
mainten
high
level
antibodi
titer
host
immun
respons
could
increas
clear
viral
infect
besid
vivo
studi
show
effect
neutral
antibodi
limit
viral
clearanc
also
includ
acceler
infect
cell
case
viral
load
estim
ct
valu
show
increas
trend
plasma
infus
began
decreas
right
use
convalesc
plasma
although
improv
inflammatori
marker
oxygen
could
contribut
combin
use
corticosteroid
decreas
viral
load
might
mean
effect
convalesc
plasma
treatment
convalesc
plasma
administ
day
onset
symptom
case
day
case
respect
earli
phase
diseas
difficult
determin
clearli
decreas
viral
load
shown
case
due
convalesc
plasma
natur
patholog
studi
viral
kinet
show
natur
reduc
viral
titer
day
onset
howev
liu
colleagu
report
sever
patient
requir
intens
care
unit
admiss
due
high
viral
load
longer
period
mild
case
present
sever
ard
viral
load
increas
trend
time
plasma
infus
regardless
date
onset
case
patient
show
lymphopenia
day
persist
even
clinic
improv
corticosteroid
use
convalesc
plasma
administ
day
lymphocyt
count
immedi
rose
normal
level
remain
normal
rang
patient
sever
pneumonia
ard
also
present
lymphopenia
author
hypothes
continu
gradual
increas
lymphocyt
count
might
requir
immun
sar
patient
lymphopenia
exist
onset
ill
persist
recoveri
find
consist
recoveri
lymphocyt
count
clinic
improv
case
use
convalesc
plasma
could
assess
neutral
antibodi
titer
convalesc
plasma
plasma
high
neutral
antibodi
titer
like
avail
patient
convalesc
phase
recov
sever
use
plasma
treatment
neutral
test
suggest
optim
assay
assess
proper
donor
plasma
howev
studi
show
elisa
igg
correl
well
neutral
titer
mer
case
might
suitabl
screen
test
plasma
case
donor
present
bilater
pneumonia
cours
show
posit
result
elisa
igg
test
still
limit
use
convalesc
plasma
scientif
evid
insuffici
due
lack
largescal
clinic
trial
may
repres
target
popul
second
number
antibodi
administ
patient
standard
final
convalesc
plasma
usual
proce
treatment
antivir
agent
steroid
affect
relationship
convalesc
plasma
antibodi
confound
result
despit
limit
case
suggest
convalesc
plasma
patient
recov
infect
might
addit
option
treat
patient
without
caus
sever
advers
effect
also
use
system
corticosteroid
might
expect
possibl
reduc
excess
inflammatori
respons
corticosteroid
well
promot
reduct
viral
load
convalesc
plasma
simultan
welldesign
studi
need
demonstr
efficaci
safeti
convalesc
plasma
transfus
patient
